A late-stage clinical trial of a drug for advanced prostate cancer was stopped this week because of positive results. All patients in the trial will now be offered the experimental drug, called MDV3100, which was found to extend survival by nearly five months.
Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program, helped discover the drug. Howard Scher, Chief of the Genitourinary Oncology Service, is the principal investigator of this phase III trial. Read about the history of this research.